Oral OA Animal Therapy Progresses via AVet Deal

• Paradigm and AVet Health sign binding terms to co-develop and license a PPS + COX-2 inhibitor oral therapy for veterinary osteoarthritis indications in Australia and New Zealand (ANZ). • Under the binding terms, AVet will hold exclusive rights in ANZ, with a first right of refusal for all other markets excluding the USA, with Paradigm eligible to receive up to A$1 million from AVet in developmen